tofacitinibまたはTNF阻害薬で治療中の関節リウマチ患者における静脈血栓塞栓症を予測するバイオマーカー
RMD Open. 2022;8(2):e002571 doi: 10.1136/rmdopen-2022-002571
Weitz, et al. analyse 291 protein biomarkers and three genetic markers and do not identify a clear mechanistic explanation for higher rates of venous thromboembolism (VTE) with tofacitinib in the ORAL Surveillance study.
Following the increased frequency of pulmonary embolism with tofacitinib 10 mg BD versus TNFi, and increased overall mortality, compared with tofacitinib 5 mg BD or TNFi, in the ORAL Surveillance study, this exploratory post hoc analysis examined whether biomarkers explained the associations of tofacitinib versus TNFi with VTE.
Keywords:
